Vasaprostan treatment of fibrosing alveolitis in patients with pulmonary hypertension
2004
Aim. To study clinical efficacy of vasaprostan in patients with fibrosing alveolitis (FA) complicated by
pulmonary hypertension (PH), its effect on functional activity of platelets and endothelium, intensity of
free radical processes.
Material and methods. Seven FA patients were examined. They had either idiopathic FA or FA with
diffuse diseases of the connective tissues. The following methods were used to assess the effect: standard clinical tests, high resolution computer tomography, Doppler echocardiography, definition of the
complex thrombin-antithrombin (TAT) and thrombocytic factor 4 (TF-4). Generation ofoxugen active
forms by leukocytes was measured by luminol-dependent chemiluminescence. Morphological verification of the diagnosis was made by the results of open pulmonary biopsies.
Results. Vasaprostan reduced pressure in the pulmonary artery from 31,6 ± 2,31 to 19,58 ± 3,90 mm
Hg (р < 0,05) and coagulation parameters. TAT decreased after 2 and 8 weeks of treatment from
15,25 ± 4,5 to 5,1 ± 0,33 and 2,4 ± 0,31 pg/ml (p < 0,05). Initially low TF-4 (2,11 ± 0,39pg/ml)
elevated to the end of the treatment and reached values close to control (4,37 ± 0,25 pg/ml,
p < 0,05). Moreover, vasaprostan enhanced the ability of platelets to inhibit generation of active oxygen forms (from 0,9 ± 0,18 to 1,23 ± 0,16 r.u., p < 0,05) and thus depressed activity of lipid peroxidation.
Conclusion. Good effect of vasaprostan on platelet activity, free radical processes validates its use in
combined treatment of various FA forms for correction of PH, its complications and as an antifibrogenic agent.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
4
Citations
NaN
KQI